UK markets closed
  • NIKKEI 225

    27,782.42
    +200.76 (+0.73%)
     
  • HANG SENG

    26,315.32
    +841.44 (+3.30%)
     
  • CRUDE OIL

    73.42
    -0.20 (-0.27%)
     
  • GOLD FUTURES

    1,832.70
    -3.10 (-0.17%)
     
  • DOW

    35,084.53
    +153.60 (+0.44%)
     
  • BTC-GBP

    28,385.36
    -524.54 (-1.81%)
     
  • CMC Crypto 200

    935.12
    +4.76 (+0.51%)
     
  • ^IXIC

    14,778.26
    +15.68 (+0.11%)
     
  • ^FTAS

    4,054.12
    +30.04 (+0.75%)
     

Karolinska Development’s portfolio company Promimic receives market clearance for HAnano Surface in orthopedic oncology in collaboration with Onkos Surgical

·2-min read

STOCKHOLM, SWEDEN – July 7, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Promimic has received a shared 501(k) clearance from the U.S. Food and Drug Administration (FDA) with the orthopedic company Oncos Surgical. The market clearance concerns the implant product BioGrip® Modular Porous Collars, developed by Onkos Surgical, which has been coated with HAnano Surface in order to treat implant loosening in orthopedic oncology and complex revision surgery.

Promimic develops and markets HAnano Surface, a unique, nanometer-thin surface technology that aims to improve the anchoring and healing of implants in bone tissue. The collaboration with Onkos Surgical addresses complex surgical procedures in large joints that occur as a result of cancer or removal of previous implants.

“We are very positive to the approval for HAnano Surface, which brings Promimic into a new product segment, implants in large joints, with expanded opportunities for development and commercialization. We look forward to continue following and supporting the company on its path onward,” comments Viktor Drvota, CEO, Karolinska Development.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting